G MEDICAL INNOVATIONS AND MICARE PATH ANNOUNCE JOINT COLLABORATION TO PROVIDE INNOVATIVE REMOTE PATIENT MONITORING SOLUTIONS GLOBALLY
27 Mars 2023 - 2:08PM
G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the
“Company” or “G Medical Innovations”), a global leader in
next-generation mobile health (mHealth) and digital health, and
MiCare Path, a leader in optimized patient care through remote
patient monitoring, today announced a collaboration to incorporate
MiCare Path’s solutions and G Medical Innovations’ solutions. As
part of the collaboration, G Medical Innovations’ hardware devices
will be integrated with MiCare’s software platform and
visualization tools to provide remote patient monitoring services.
The partnership brings together two innovative companies with a
shared vision of transforming the healthcare industry by leveraging
technology and providing patient-centered care. MiCare Path
brings its large hospital system presence and optimized
patient care platform to drive digital science to deliver the
future of healthcare. G Medical Innovations was a chosen
partner for MiCare Path due to its innovative and scalable solution
for building and fostering health technology.
Under the terms of the agreement, the Company will be
responsible for the server integration of its devices into MiCare’s
platform. MiCare will be responsible for all support and
information technology (“IT”) integration pertaining to their
patient application. The agreement has a term until December 31,
2024, unless terminated earlier, and will automatically renew for
one year thereafter (repeating each calendar year).
“This collaboration with MiCare Path, allows us to pivot towards
innovative approaches in remote patient monitoring while delivering
an automated comprehensive system of patient engagement, behavioral
change, and interactive communication,” said Dr. Yacov Geva,
CEO of G Medical Innovations, which has patient monitoring services
located in Austin, Texas and Memphis, Tennessee. “By
integrating MiCare Path’s virtual health solutions with G Medical’s
global health solutions and devices, physicians and patients will
benefit from the next-generation care driving better outcomes for
patients across all services,” said Scott Laster, founder and CEO
of MiCare Path. “The G Medical collaboration will allow for a total
remote patient monitoring (RPM) and remote therapeutic monitoring
(RTM) solution from service to exceptional future solutions.”
About G Medical Innovations Holdings
Ltd.
G Medical Innovations Holdings Ltd. is a healthcare company
engaged in the development of next generation mHealth and
telemedicine solutions and monitoring service platforms. The
Company’s solutions and services can empower consumers, patients,
and providers to better monitor, manage and improve clinical and
personal health outcomes, especially for those who suffer from
cardiovascular disease (or CVD), pulmonary disease, and diabetes.
The Company’s current product lines consist of its Prizma medical
device (or Prizma), a clinical-grade device that can transform
almost any smartphone into a medical monitoring device, enabling
both healthcare providers and individuals to monitor, manage and
share a wide range of vital signs and biometric indicators; its
Extended Holter and Monitoring Cardiac Telemetry Patch services,
utilizing a multi-channel patient-worn biosensors, with algorithms
for real time analysis and transmission that captures
electrocardiography (i.e. ECG) data continuously, including QT
Syndrome Prolongation Detection. In addition, the Company is
developing its Wireless Vital Signs Monitoring System (or VSMS),
which is expected to provide full, continuous, and real-time
monitoring of a wide range of vital signs and biometrics. Its
monitoring services include provision of Independent Diagnostic
Testing Facility (i.e., IDTF) monitoring services and private
monitoring services.
In the second half of 2022, the Company expanded its business
activities into a new business area, at-home laboratory testing
kits. In the third quarter of 2023, the Company expects that users
will be able to purchase a sample collection kit at retail stores
or online and collect their sample from the comfort and privacy of
their home and send it via mail to the Company’s certified lab for
analysis. The Company has developed 31 types of tests kits which
can test a wide range health issued related to hormones, sexual
transferred disease, colon cancer, nutrition, food sensitivities
and allergies. In addition, the Company’s pipeline includes
development of additional kits for drug detection, heavy metal and
toxicology. Data received from both vital signs and lab tests
reflects the vision of the Company which is to allow users to
create their personal electronic medical records and manage their
health in one location which is available for them anywhere and
anytime without dependency on any medical organization.
For more information about G Medical Innovations,
visit https://gmedinnovations.com/.
About MiCare
Path
MiCare Path is transforming the way in which chronic conditions
are managed by providing real-time connectivity with an
ever-growing patient population. MiCare Path is a reimbursable,
integrated mobile health (mHealth) platform delivering
improved outcomes with data-driven decisions, personalized
patient-centered education and care paths promoting clinical
efficiencies for a better patient experience. They empower people
to take control of their health through innovative monitoring and
management of all health conditions by removing barriers to patient
engagement and leading to better health. For more information,
visit micarepath.com.
Forward-Looking
Statements:
This press release contains forward-looking statements within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as “expects,” “anticipates,” “intends,”
“plans,” “believes,” “seeks,” “estimates,” and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, G Medical Innovations is
using forward-looking statements when it discusses the benefits of
its collaboration with MiCare Path. Because such statements deal
with future events and are based on the Company’s current
expectations, they are subject to various risks and uncertainties,
and actual results, performance, or achievements of G Medical
Innovations could differ materially from those described in or
implied by the statements in this press release. The
forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties. Except as
otherwise required by law, G Medical Innovations undertakes no
obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release.
G Medical Innovations (NASDAQ:GMVD)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
G Medical Innovations (NASDAQ:GMVD)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024